MX351189B - Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares. - Google Patents
Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.Info
- Publication number
- MX351189B MX351189B MX2014001764A MX2014001764A MX351189B MX 351189 B MX351189 B MX 351189B MX 2014001764 A MX2014001764 A MX 2014001764A MX 2014001764 A MX2014001764 A MX 2014001764A MX 351189 B MX351189 B MX 351189B
- Authority
- MX
- Mexico
- Prior art keywords
- alpha1
- delaying
- onset
- progression
- proteinase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0018—Details of inhalators; Constructional features thereof with exhalation check valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0085—Inhalators using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un inhibidor de Alpha1-proteinasa (A1P1) para usarse en disminuir la progresión de uno o más de un primer conjunto de síntomas asociados con exacerbaciones pulmonares de empeoramiento y/o aumento de la severidad en un individuo en necesidad del mismo. Uso de inhibidor de Apha1-proteinasa (A1P1) para preparar un medicamento para disminuir la progresión de uno o más de un primer conjunto de síntomas asociados con exacerbaciones pulmonares de empeoramiento y/o aumento de la severidad en un individuo en necesidad del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161581708P | 2011-12-30 | 2011-12-30 | |
PCT/IB2012/056616 WO2013098672A2 (en) | 2011-12-30 | 2012-11-22 | Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014001764A MX2014001764A (es) | 2014-04-30 |
MX351189B true MX351189B (es) | 2017-10-04 |
Family
ID=47470050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014001764A MX351189B (es) | 2011-12-30 | 2012-11-22 | Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares. |
Country Status (19)
Country | Link |
---|---|
US (1) | US9421248B2 (es) |
EP (1) | EP2758065B1 (es) |
JP (4) | JP2015504051A (es) |
KR (1) | KR20140108516A (es) |
CN (2) | CN103889436A (es) |
AR (2) | AR088971A1 (es) |
AU (1) | AU2012337241B2 (es) |
BR (1) | BR112014007127A2 (es) |
CA (1) | CA2844878C (es) |
CL (1) | CL2014000722A1 (es) |
ES (1) | ES2887358T3 (es) |
HK (1) | HK1198918A1 (es) |
IL (1) | IL231109B (es) |
MX (1) | MX351189B (es) |
MY (1) | MY166314A (es) |
RU (1) | RU2635482C2 (es) |
SG (2) | SG2014012066A (es) |
UY (1) | UY34465A (es) |
WO (1) | WO2013098672A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160054475A (ko) * | 2013-08-05 | 2016-05-16 | 제라드 뵈르만 | 흡연의 해로운 영향을 감소시키는 신규의 수단 |
JP6783767B2 (ja) * | 2014-12-22 | 2020-11-11 | アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. | 組換えタンパク質を精製する方法 |
US11446366B2 (en) * | 2015-02-05 | 2022-09-20 | Canem Holdings, Llc | Compositions and methods for treating granulomatosis with polyangiitis |
WO2018154568A1 (en) * | 2017-02-21 | 2018-08-30 | Kamada Ltd. | Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases |
US10663434B2 (en) * | 2017-03-31 | 2020-05-26 | Sonix, Inc. | Wafer chuck |
WO2021028927A1 (en) * | 2019-08-15 | 2021-02-18 | Kamada Ltd | Combination of alpha-1-antitrypsin and steroids and uses therefor |
JP2022544834A (ja) * | 2019-08-23 | 2022-10-21 | ピーエイチ・ファーマ・カンパニー・リミテッド | 肺疾患における好中球エラスターゼ阻害剤の使用 |
US20230302104A1 (en) * | 2020-05-01 | 2023-09-28 | Atlas Biotechnology S.A. | Treatment and/or prevention of a disease or a syndrome related to a virus infection |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE395611B (sv) | 1975-12-12 | 1977-08-22 | Draco Ab | Aerosolinhalationsanordning avsedd for inhalering genom ett inhaleringsmunstycke av farmakologiskt aktiva substanser |
SE411705B (sv) | 1976-11-09 | 1980-02-04 | Draco Ab | Anordning for generering av en avskermad, vesentligen drivmedelsfri aerosol |
CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
US5218091A (en) | 1982-08-13 | 1993-06-08 | Zymogenetics, Inc. | Glycolytic promoters for regulated protein expression: protease inhibitor |
US4667688A (en) | 1983-11-28 | 1987-05-26 | Francisco Roig | Mini pack of cigarettes |
US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
US4732973A (en) | 1984-06-14 | 1988-03-22 | Chiron Corporation | Active site modified protease α-1-antitrypsin inhibitors |
JP2599585B2 (ja) | 1984-06-19 | 1997-04-09 | トランスジ−ン ソシエテ アノニム | ヒトα▲下1▼−アンチトリプシン誘導体及びその製造法 |
US4697003A (en) | 1985-11-01 | 1987-09-29 | Miles Laboratories, Inc. | Method of preparing alpha-1-proteinase inhibitor |
US5322775A (en) | 1986-06-30 | 1994-06-21 | Pharmaceutical Proteins Ltd. | Peptide production |
US5114917A (en) | 1986-12-24 | 1992-05-19 | John Lezdey | Treatment of inflammation using alpha 1-antichymotrypsin |
JP2656944B2 (ja) | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | タンパク質性治療剤のエアロゾール化 |
US5079336A (en) | 1989-06-23 | 1992-01-07 | The Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin, analogues and methods of production |
US5134119A (en) | 1990-10-16 | 1992-07-28 | Lezdey John | Treatment of inflammation using 358 substituted alpha-antitrypsin |
US5915378A (en) | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
DK0748213T3 (da) | 1994-03-07 | 2004-08-02 | Nektar Therapeutics | Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin |
CA2190502A1 (en) | 1994-05-18 | 1995-11-23 | Robert M. Platz | Methods and compositions for the dry powder formulation of interferons |
US5610285A (en) | 1994-08-24 | 1997-03-11 | Bayer Corporation | Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
AU6884396A (en) | 1995-09-07 | 1997-03-27 | Ppl Therapeutics (Scotland) Ltd | Purification of alpha-1 proteinase inhibitor |
US5780440A (en) | 1996-06-17 | 1998-07-14 | Protease Sciences Inc. | Treatment of pulmonary disease with protease inhibitors |
AT407114B (de) | 1997-06-10 | 2000-12-27 | Immuno Ag | Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung |
PL343276A1 (en) | 1998-03-16 | 2001-08-13 | Inhale Therapeutic Syst | Aerosolized active agent delivery |
US6093804A (en) | 1998-09-24 | 2000-07-25 | American National Red Cross | Method for purification of alpha-1 proteinase inhibitor |
US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
DE19953317C1 (de) * | 1999-11-05 | 2001-02-01 | Pari Gmbh | Inhalationsvernebler |
US6462180B1 (en) | 1999-11-24 | 2002-10-08 | Bayer Corporation | Method of preparing α-1 proteinase inhibitor |
WO2002050287A2 (en) | 2000-12-18 | 2002-06-27 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
WO2005027821A2 (en) | 2003-09-22 | 2005-03-31 | Kamada Ltd. | Large scale preparation of alpha-1 proteinase inhibitor and use thereof |
ATE530165T1 (de) * | 2003-11-14 | 2011-11-15 | Baxter Int | Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen |
US7914771B2 (en) | 2004-03-09 | 2011-03-29 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
EP2740487B1 (en) * | 2006-02-09 | 2018-02-28 | Kamada Ltd. | Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases |
US20080078382A1 (en) | 2006-09-20 | 2008-04-03 | Lemahieu Edward | Methods and Systems of Delivering Medication Via Inhalation |
EP1927373B1 (en) | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
NZ590257A (en) | 2008-07-18 | 2012-08-31 | Grifols Therapeutics Inc | Method of preparing alpha-1 proteinase inhibitor |
ES2679819T3 (es) | 2009-11-03 | 2018-08-31 | Grifols Therapeutics Inc. | Composición, método y kit para inhibidor de alfa-1 proteinasa |
-
2012
- 2012-11-22 SG SG2014012066A patent/SG2014012066A/en unknown
- 2012-11-22 ES ES12808897T patent/ES2887358T3/es active Active
- 2012-11-22 KR KR1020147006804A patent/KR20140108516A/ko not_active Application Discontinuation
- 2012-11-22 BR BR112014007127A patent/BR112014007127A2/pt not_active Application Discontinuation
- 2012-11-22 MY MYPI2014700341A patent/MY166314A/en unknown
- 2012-11-22 CA CA2844878A patent/CA2844878C/en active Active
- 2012-11-22 CN CN201280048668.2A patent/CN103889436A/zh active Pending
- 2012-11-22 RU RU2014106758A patent/RU2635482C2/ru active
- 2012-11-22 AU AU2012337241A patent/AU2012337241B2/en active Active
- 2012-11-22 CN CN201710789166.XA patent/CN107596359A/zh active Pending
- 2012-11-22 EP EP12808897.8A patent/EP2758065B1/en active Active
- 2012-11-22 WO PCT/IB2012/056616 patent/WO2013098672A2/en active Application Filing
- 2012-11-22 SG SG10201610913PA patent/SG10201610913PA/en unknown
- 2012-11-22 US US14/369,662 patent/US9421248B2/en active Active
- 2012-11-22 JP JP2014549567A patent/JP2015504051A/ja active Pending
- 2012-11-22 MX MX2014001764A patent/MX351189B/es active IP Right Grant
- 2012-11-23 AR ARP120104411A patent/AR088971A1/es not_active Application Discontinuation
- 2012-11-23 UY UY0001034465A patent/UY34465A/es not_active Application Discontinuation
-
2014
- 2014-02-24 IL IL231109A patent/IL231109B/en active IP Right Grant
- 2014-03-24 CL CL2014000722A patent/CL2014000722A1/es unknown
- 2014-12-10 HK HK14112415.6A patent/HK1198918A1/xx unknown
-
2016
- 2016-10-05 JP JP2016197058A patent/JP2017039745A/ja active Pending
-
2018
- 2018-01-25 JP JP2018010440A patent/JP2018104439A/ja active Pending
-
2019
- 2019-04-02 JP JP2019070581A patent/JP2019135243A/ja active Pending
- 2019-10-29 AR ARP190103126A patent/AR116887A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN107596359A (zh) | 2018-01-19 |
AR116887A2 (es) | 2021-06-23 |
ES2887358T3 (es) | 2021-12-22 |
SG2014012066A (en) | 2014-09-26 |
EP2758065A2 (en) | 2014-07-30 |
US9421248B2 (en) | 2016-08-23 |
AR088971A1 (es) | 2014-07-23 |
MX2014001764A (es) | 2014-04-30 |
CA2844878A1 (en) | 2013-07-04 |
UY34465A (es) | 2013-07-31 |
AU2012337241A1 (en) | 2013-07-18 |
RU2014106758A (ru) | 2015-08-27 |
US20150011460A1 (en) | 2015-01-08 |
CN103889436A (zh) | 2014-06-25 |
NZ621596A (en) | 2016-08-26 |
RU2635482C2 (ru) | 2017-11-13 |
MY166314A (en) | 2018-06-25 |
SG10201610913PA (en) | 2017-02-27 |
EP2758065B1 (en) | 2021-06-23 |
JP2018104439A (ja) | 2018-07-05 |
KR20140108516A (ko) | 2014-09-11 |
JP2017039745A (ja) | 2017-02-23 |
BR112014007127A2 (pt) | 2017-04-04 |
WO2013098672A2 (en) | 2013-07-04 |
CL2014000722A1 (es) | 2014-10-10 |
IL231109B (en) | 2018-02-28 |
AU2012337241B2 (en) | 2016-10-13 |
HK1198918A1 (en) | 2015-06-19 |
WO2013098672A3 (en) | 2013-10-24 |
IL231109A0 (en) | 2014-04-30 |
JP2019135243A (ja) | 2019-08-15 |
CA2844878C (en) | 2017-11-28 |
JP2015504051A (ja) | 2015-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX355728B (es) | Inhibidores de cinasas. | |
MX351189B (es) | Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares. | |
HK1213251A1 (zh) | 作為突變 抑制劑的 -嘧啶- -基-噁唑烷- -酮化合物 | |
PH12015502141A1 (en) | Substituted xanthines and methods of use thereof | |
HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
EP3113772A4 (en) | Human plasma kallikrein inhibitors | |
EP2714081A4 (en) | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT | |
MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
MX2013010475A (es) | Composiciones inmunoterapeuticas de levadura-brachyuri. | |
PH12014501273A1 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
MY168300A (en) | Pharmaceutical Composition for Inhalation | |
EP3033101A4 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
IN2014CN04050A (es) | ||
CA2843611C (en) | Compositions and methods for reducing the incidence of equine digestive disorders | |
EP3244968A4 (en) | Combination therapy for pulmonary hypertension | |
IN2014CN00312A (es) | ||
EP3182983A4 (en) | Antibodies to polyphosphate decrease clot formation, decrease inflammation, and improve survival | |
WO2012106702A3 (en) | Treatment of leukemia | |
WO2014008204A3 (en) | Structures of proteasome inhibitors and methods for synthesizing and use thereof | |
WO2012139074A3 (en) | Migrastatins and uses thereof | |
IN2014CN02585A (es) | ||
EA201391421A1 (ru) | Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана | |
EA201391419A1 (ru) | Пролекарства d-изоглутамил-[d/l]-триптофана |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |